Catalyst Event

Bristol-Myers Squibb Co (BMY) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

6/17/2026, 12:00:00 AM

OtherSentiment: Positive

Presented new clinical data for pipeline candidates mezigdomide and arlocabtagene autoleucel on June 17, 2026, at the EHA Congress. Low importance due to incremental clinical data updates; expected

Korean Translation

2026년 6월 17일 유럽혈액학회(EHA)에서 다발성 골수종 후보물질 임상 데이터 발표. 점진적인 데이터 업데이트로 낮은 중요도가 예상됨

Related Recent Events

View Full Timeline